The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages
Abstract
Tumor-associated macrophages (TAMs) are a promising therapeutic target for cancer immunotherapy. Targeted delivery of therapeutic drugs to the tumor-promoting M2-like TAMs is challenging. Here, we developed M2-like TAM dual-targeting nanoparticles (M2NPs), whose structure and function were controlled by α-peptide (a scavenger receptor B type 1 (SR-B1) targeting peptide) linked with M2pep (an M2 macrophage binding peptide). By loading anti-colony stimulating factor-1 receptor (anti-CSF-1R) small interfering RNA (siRNA) on the M2NPs, we developed a molecular-targeted immunotherapeutic approach to specifically block the survival signal of M2-like TAMs and deplete them from melanoma tumors. We confirmed the validity of SR-B1 for M2-like TAM targeting and demonstrated the synergistic effect of the two targeting units (α-peptide and M2pep) in the fusion peptide (α-M2pep). After being administered to tumor-bearing mice, M2NPs had higher affinity to M2-like TAMs than to tissue-resident macrophages in liver, spleen, and lung. Compared with control treatment groups, M2NP-based siRNA delivery resulted in a dramatic elimination of M2-like TAMs (52%), decreased tumor size (87%), and prolonged survival. Additionally, this molecular-targeted strategy inhibited immunosuppressive IL-10 and TGF-β production and increased immunostimulatory cytokines (IL-12 and IFN-γ) expression and CD8 + T cell infiltration (2.9-fold) in the tumor microenvironment. Moreover, the siRNA-carrying M2NPs down-regulated expression of the exhaustion markers (PD-1 and Tim-3) on the infiltrating CD8 + T cells and stimulated their IFN-γ secretion (6.2-fold), indicating the restoration of T cell immune function. Thus, the dual-targeting property of M2NPs combined with RNA interference provides a potential strategy of molecular-targeted cancer immunotherapy for clinical application.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Macrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
Protective and pathogenic functions of macrophage subsets
Murray, P. J., & Wynn, T. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri3073 · Cited by 5,269
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
Sallusto, F., Cella, M., Danieli, C., & Lanzavecchia, A. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.389 · Cited by 2,500
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy
Lin, E. Y., Nguyen, A. V., Russell, R. G., & Pollard, J. W. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.6.727 · Cited by 1,594
van Dam, G. M., Themelis, G., Crane, L. M. A., Harlaar, N. J., Pleijhuis, R. G., Kelder, W., Sarantopoulos, A., de Jong, J. S., Arts, H. J. G., van der Zee, A. G. J., et al. (2011) · Nature Medicine · doi:10.1038/nm.2472 · Cited by 1,545
Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L. P., Feuerhake, F., Klaman, I., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.016 · Cited by 1,384
DeNardo, D. G., Barreto, J. B., Andreu, P., Vasquez, L., Tawfik, D., Kolhatkar, N., & Coussens, L. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.018 · Cited by 1,353
Zhu, Y., Knolhoff, B. L., Meyer, M. A., Nywening, T. M., West, B. L., Luo, J., Wang-Gillam, A., Goedegebuure, S. P., Linehan, D. C., & DeNardo, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3723 · Cited by 1,324
Colony-stimulating factors in inflammation and autoimmunity
Hamilton, J. A. (2008) · Nature reviews. Immunology · doi:10.1038/nri2356 · Cited by 1,305
Liver immunology and its role in inflammation and homeostasis
Robinson, M. W., Harmon, C., & O’Farrelly, C. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2016.3 · Cited by 1,151
Macrophage death and defective inflammation resolution in atherosclerosis
Tabas, I. (2010) · Nature Reviews Immunology · doi:10.1038/nri2675 · Cited by 1,120
Macrophage Regulation of Tumor Responses to Anticancer Therapies
De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079
Ruffell, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C. M. T., Pryer, N., Daniel, D., Hwang, E. S., Rugo, H. S., & Coussens, L. M. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.006 · Cited by 1,008
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A., Pochanard, P., Kehoe, S. M., Johannessen, C. M., MacConaill, L. E., Hahn, W. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.2312 · Cited by 1,005
Okabe, Y., & Medzhitov, R. (2014) · Cell · doi:10.1016/j.cell.2014.04.016 · Cited by 884
Hume, D. A., & MacDonald, K. P. A. (2012) · Blood · doi:10.1182/blood-2011-09-379214 · Cited by 763
Macrophages and cancer: from mechanisms to therapeutic implications
Ostuni, R., Kratochvill, F., Murray, P. J., & Natoli, G. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.004 · Cited by 683
The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas
Quail, D. F., Bowman, R. L., Akkari, L., Quick, M. L., Schuhmacher, A. J., Huse, J. T., Holland, E. C., Sutton, J. C., & Joyce, J. A. (2016) · Science · doi:10.1126/science.aad3018 · Cited by 666
Pluen, A., Boucher, Y., Ramanujan, S., McKee, T. D., Gohongi, T., di Tomaso, E., Brown, E. B., Izumi, Y., Campbell, R. B., Berk, D. A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081626898 · Cited by 603
Xu, J., Escamilla, J., Mok, S., David, J., Priceman, S., West, B., Bollag, G., McBride, W., & Wu, L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3981 · Cited by 569
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
Guerriero, J. L., Sotayo, A., Ponichtera, H. E., Castrillon, J. A., Pourzia, A. L., Schad, S., Johnson, S. F., Carrasco, R. D., Lazo, S., Bronson, R. T., et al. (2017) · Nature · doi:10.1038/nature21409 · Cited by 558
Targeting tumor-associated macrophages as a novel strategy against breast cancer
Luo, Y. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27648 · Cited by 552
A multifunctional core–shell nanoparticle for dendritic cell-based cancer immunotherapy
Cho, N.-H., Cheong, T.-C., Min, J. H., Wu, J. H., Lee, S. J., Kim, D., Yang, J.-S., Kim, S., Kim, Y. K., & Seong, S.-Y. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.149 · Cited by 514
Prima, V., Kaliberova, L. N., Kaliberov, S., Curiel, D. T., & Kusmartsev, S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612920114 · Cited by 494
Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival
Cieslewicz, M., Tang, J., Yu, J. L., Cao, H., Zavaljevski, M., Motoyama, K., Lieber, A., Raines, E. W., & Pun, S. H. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312197110 · Cited by 314
MRI of Tumor-Associated Macrophages with Clinically Applicable Iron Oxide Nanoparticles
Daldrup-Link, H. E., Golovko, D., Ruffell, B., DeNardo, D. G., Castaneda, R., Ansari, C., Rao, J., Tikhomirov, G. A., Wendland, M. F., Corot, C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3420 · Cited by 300
Conde, J., Bao, C., Tan, Y., Cui, D., Edelman, E. R., Azevedo, H. S., Byrne, H. J., Artzi, N., & Tian, F. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201501283 · Cited by 238
Zhu, S., Niu, M., O’Mary, H., & Cui, Z. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400216r · Cited by 232
Characterization of murine macrophages from bone marrow, spleen and peritoneum
Wang, C., Yu, X., Cao, Q., Wang, Y., Zheng, G., Tan, T. K., Zhao, H., Zhao, Y., Wang, Y., & Harris, D. C. (2013) · BMC Immunology · doi:10.1186/1471-2172-14-6 · Cited by 225
Self-citationCuellar, T. L., Barnes, D., Nelson, C., Tanguay, J., Yu, S.-F., Wen, X., Scales, S. J., Gesch, J., Davis, D., van Brabant Smith, A., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1362 · Cited by 213
An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy
Chen, Y., Xia, R., Huang, Y., Zhao, W., Li, J., Zhang, X., Wang, P., Venkataramanan, R., Fan, J., Xie, W., et al. (2016) · Nature Communications · doi:10.1038/ncomms13443 · Cited by 190
Macrophages retain hematopoietic stem cells in the spleen via VCAM-1
Dutta, P., Hoyer, F. F., Grigoryeva, L. S., Sager, H. B., Leuschner, F., Courties, G., Borodovsky, A., Novobrantseva, T., Ruda, V. M., Fitzgerald, K., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20141642 · Cited by 180
Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy
Huang, Z., Zhang, Z., Jiang, Y., Zhang, D., Chen, J., Dong, L., & Zhang, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.013 · Cited by 169
Self-citationQian, Y., Jin, H., Qiao, S., Dai, Y., Huang, C., Lu, L., Luo, Q., & Zhang, Z. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.05.008 · Cited by 159
Self-citationHDL‐Mimicking Peptide–Lipid Nanoparticles with Improved Tumor Targeting
Zhang, Z., Chen, J., Ding, L., Jin, H., Lovell, J. F., Corbin, I. R., Cao, W., Lo, P., Yang, M., Tsao, M., et al. (2009) · Small · doi:10.1002/smll.200901515 · Cited by 147
Self-citationOut, R., Hoekstra, M., Spijkers, J. A. A., Kruijt, J. K., Eck, M. V., Bos, I. S. T., Twisk, J., & van Berkel, T. J. C. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400191-jlr200 · Cited by 138
Distinct development and functions of resident and recruited liver Kupffer cells/macrophages
Ikarashi, M., Nakashima, H., Kinoshita, M., Sato, A., Nakashima, M., Miyazaki, H., Nishiyama, K., Yamamoto, J., & Seki, S. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0313144 · Cited by 132
Huang, C., Jin, H., Qian, Y., Qi, S., Luo, H., Luo, Q., & Zhang, Z. (2013) · ACS Nano · doi:10.1021/nn400683s · Cited by 131
Self-citationTargeting of macrophage galactose‐type C ‐type lectin ( MGL ) induces DC signaling and activation
Napoletano, C., Zizzari, I. G., Rughetti, A., et al. (2012) · European Journal of Immunology · doi:10.1002/eji.201142086 · Cited by 109
Movita, D., Kreefft, K., Biesta, P. J., van Oudenaren, A., Leenen, P. J. M., Janssen, H. L. A., & Boonstra, A. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.1111566 · Cited by 98
Qi, S., Li, H., Lu, L., Qi, Z., Liu, L., Chen, L., Shen, G., Fu, L., Luo, Q., & Zhang, Z. (2016) · eLife · doi:10.7554/elife.14756 · Cited by 56
Self-citationNasopharyngeal Cancer-Specific Therapy Based on Fusion Peptide-Functionalized Lipid Nanoparticles
Luo, H., Lu, L., Yang, F., Wang, L., Yang, X., Luo, Q., & Zhang, Z. (2014) · ACS Nano · doi:10.1021/nn405989n · Cited by 45
Self-citationLin, Q., Chen, J., Jin, H., Ng, K. K., Yang, M., Cao, W., Ding, L., Zhang, Z., & Zheng, G. (2012) · Nanomedicine · doi:10.2217/nnm.12.73 · Cited by 40
Self-citationZasłona, Z., Wilhelm, J., Cakarova, L., Marsh, L. M., Seeger, W., Lohmeyer, J., & von Wulffen, W. (2009) · Respiratory Research · doi:10.1186/1465-9921-10-2 · Cited by 34
Gold nanoparticles for cancer theranostics — A brief update
Zhao, N., Pan, Y., Cheng, Z., & Liu, H. (2016) · Journal of Innovative Optical Health Sciences · doi:10.1142/s1793545816300044 · Cited by 28
Cited by
Engineering Macrophages for Cancer Immunotherapy and Drug Delivery
Xia, Y., Rao, L., Yao, H., Wang, Z., Ning, P., & Chen, X. (2020) · Advanced Materials · doi:10.1002/adma.202002054 · Cited by 949
Enhancing cancer immunotherapy with nanomedicine
Irvine, D. J., & Dane, E. L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0269-6 · Cited by 882
The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment
Yang, M., Li, J., Gu, P., & Fan, X. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.12.010 · Cited by 670
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Tie, Y., Tang, F., Wei, Y.-Q., & Wei, X.-W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01282-8 · Cited by 591
Yang, Q., Guo, N., Zhou, Y., Chen, J., Wei, Q., & Han, M. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.04.004 · Cited by 471
Metadata
- Authors
- Qian, Y., Qiao, S., Dai, Y., Xu, G., Dai, B., Lu, L., Yu, X., Luo, Q., & Zhang, Z.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-09-06
- Volume
- 11
- Issue
- 9
- Pages
- 9536-9549
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2751194532
- Cited by
- 333
- References
- 59
- FWCI
- 10.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.